Table 2.

Spotting and bleeding and bothersome assessment in the first month of using a contraceptive vaginal ring releasing estradiol 75 mcg, 100 mcg, or 200 mcg per day and segesterone acetate 200 mcg per day

	E2 75 mcg/day and SA 200 mcg/day n=22	E2 100 mcg/day and SA 200 mcg/day n=21	E2 200 mcg/day and SA 200 mcg/day n=22
Week 1*ǂ
Spotting	7 (31.8)	3 (14.3)	6 (27.3)
Bothersome	0	1 (33.3)	2 (33.3)
Bleeding	8 (36.4)	2 (9.5)	6 (27.3)
Bothersome	0	0	3 (50.0)
Week 2*
Spotting	4 (18.2)	5 (23.8)	1 (4.5)
Bothersome	3 (75.0)	2 (40.0)	1 (100)
Bleeding	1 (4.5)	4 (19.0)	0
Bothersome	1 (100)	4 (100)	0
Week 3*
Spotting	7 (31.8)	5 (23.8)	0
Bothersome	5 (71.4)	4 (80.0)	0
Bleeding	4 (18.2)	4 (19.0)	0
Bothersome	4 (100)	2 (50.0)	0
Week 4*
Spotting	10 (45.5)	8 (38.1)	0
Bothersome	5 (50.0)	7 (87.5)	0
Bleeding	7 (31.8)	4 (19.0)	1 (4.5)
Bothersome	5 (71.4)	2 (50.0)	1 (100)

^*Participants reported bleeding or spotting in week prior. Bothersome assessment done in participants who reported spotting or bleeding.

^ǂParticipants initiated ring use during menses so the bleeding and spotting in week 1 include residual menses from a cycle prior to treatment.

Data presented as n (%); SA = Segesterone Acetate; E2 = estradiol